Tetraphase Pharmaceuticals Receives Consensus Recommendation of “Buy” from Brokerages (NASDAQ:TTPH)
Tetraphase Pharmaceuticals (NASDAQ:TTPH) has been given an average rating of “Buy” by the ten brokerages that are currently covering the company, American Banking News reports. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $19.25.
Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded up 1.20% on Thursday, hitting $15.19. The stock had a trading volume of 6,756 shares. Tetraphase Pharmaceuticals has a 52 week low of $8.01 and a 52 week high of $17.74. The stock’s 50-day moving average is $11.51 and its 200-day moving average is $11.44. The company’s market cap is $394.2 million.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by $0.17. The company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $2.79 million. On average, analysts predict that Tetraphase Pharmaceuticals will post $-2.32 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on TTPH shares. Analysts at JMP Securities raised their price target on shares of Tetraphase Pharmaceuticals from $16.00 to $20.00 in a research note on Wednesday. They now have an “outperform” rating on the stock. Separately, analysts at Brean Capital initiated coverage on shares of Tetraphase Pharmaceuticals in a research note on Tuesday, July 8th. They set a “buy” rating and a $23.00 price target on the stock. Finally, analysts at TheStreet upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 20th.
Tetraphase Pharmaceuticals, Inc, incorporated on July 7, 2006, is a clinical stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.